BACKGROUND: Human papillomavirus (HPV) represents a potential risk factor for squamous cell cancer of the head and neck (SCCHN). We evaluated the prevalence of HPV DNA in patients with SCCHN diagnosed at the University of Michigan from 1994-1996. METHODS: Patients were stratified by age at diagnosis as "young" (<50 years; median, 39) or "old" (>50 years; median, 66). Fourteen "young" and 14 "old" were matched for tumor site, and 4 additional "old" patients were included. Specimens were analyzed by polymerase chain reaction for HPV DNA using 2 sets of consensus primers. HPV sequences were confirmed by Southern blot hybridization and typed with type-specific probes. RESULTS: Overall, 15 of 32 (46.9%) samples contained HPV sequences. HPV 16 was detected in 9 of 15 (60%), HPV-18 in 1 of 15 (6.6%), and 5 of 15 (33.3%) remained untyped by multiple methods. When stratified, 7 of 14 (50%) "young" were HPV-positive compared with 8 of 18 (44.4%) "old" (p =.76). Survival in patients with HPV-positive SCCHN was significantly longer than that for HPV-negative patients. CONCLUSIONS: The incidence of HPV in "young" versus "old" is not significantly different, suggesting similar roles for both groups. Patients with HPV-positive tumors may have a survival advantage relative to patients with HPV-negative tumors. Copyright 2000 John Wiley & Sons, Inc.
BACKGROUND:Human papillomavirus (HPV) represents a potential risk factor for squamous cell cancer of the head and neck (SCCHN). We evaluated the prevalence of HPV DNA in patients with SCCHN diagnosed at the University of Michigan from 1994-1996. METHODS:Patients were stratified by age at diagnosis as "young" (<50 years; median, 39) or "old" (>50 years; median, 66). Fourteen "young" and 14 "old" were matched for tumor site, and 4 additional "old" patients were included. Specimens were analyzed by polymerase chain reaction for HPV DNA using 2 sets of consensus primers. HPV sequences were confirmed by Southern blot hybridization and typed with type-specific probes. RESULTS: Overall, 15 of 32 (46.9%) samples contained HPV sequences. HPV 16 was detected in 9 of 15 (60%), HPV-18 in 1 of 15 (6.6%), and 5 of 15 (33.3%) remained untyped by multiple methods. When stratified, 7 of 14 (50%) "young" were HPV-positive compared with 8 of 18 (44.4%) "old" (p =.76). Survival in patients with HPV-positive SCCHN was significantly longer than that for HPV-negative patients. CONCLUSIONS: The incidence of HPV in "young" versus "old" is not significantly different, suggesting similar roles for both groups. Patients with HPV-positive tumors may have a survival advantage relative to patients with HPV-negative tumors. Copyright 2000 John Wiley & Sons, Inc.
Authors: Evgenia Gubanova; Brandee Brown; Sergei V Ivanov; Thomas Helleday; Gordon B Mills; Wendell G Yarbrough; Natalia Issaeva Journal: Clin Cancer Res Date: 2012-01-13 Impact factor: 12.531
Authors: J P Klussmann; S Dinh; O Guntinas-Lichius; C Wittekindt; S Weissenborn; U Wieland; H P Dienes; T Hoffmann; E Smith; L Turek; E J M Speel; H J Pfister Journal: HNO Date: 2004-03 Impact factor: 1.284
Authors: Jens P Klussmann; Soenke J Weissenborn; Ulrike Wieland; Volker Dries; Hans E Eckel; Herbert J Pfister; Pawel G Fuchs Journal: Med Microbiol Immunol Date: 2002-09-14 Impact factor: 3.402
Authors: Vito Rodolico; Walter Arancio; Marco C Amato; Francesco Aragona; Francesco Cappello; Olga Di Fede; Giuseppe Pannone; Giuseppina Campisi Journal: Infect Agent Cancer Date: 2011-10-27 Impact factor: 2.965
Authors: Kunsong Huang; Guoying Ni; Bowei Ma; Shu Chen; Yi Luan; Tianfang Wang; Shelley Walton; Ian Frazer; Xiaosong Liu; Xuan Pan Journal: J Int Med Res Date: 2020-01 Impact factor: 1.671